Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

NCT03838796 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

297

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: lenvatinib
PROCEDURE: TACE

Sponsor

Fudan University